Latest On Fortress Biotech, Inc (FBIOP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-04-12 06:14 EST | Dividend | A dividend of $0.2 has been announced on Apr 8, 2024. It will be paid Apr 30, 2024 with an ex-dividend date of Apr 12, 2024. | Neutral |  |
| 2024-03-14 06:22 EST | Dividend | A dividend of $0.2 has been announced on Mar 6, 2024. It will be paid Mar 31, 2024 with an ex-dividend date of Mar 14, 2024. | Neutral | |
| 2024-02-14 05:39 EST | Dividend | A dividend of $0.2 has been announced on Feb 6, 2024. It will be paid Feb 29, 2024 with an ex-dividend date of Feb 14, 2024. | Neutral | |
| 2024-01-11 05:40 EST | Dividend | A dividend of $0.2 has been announced on Jan 8, 2024. It will be paid Jan 31, 2024 with an ex-dividend date of Jan 11, 2024. | Neutral | |
| 2023-12-14 05:15 EST | Dividend | A dividend of $0.2 has been announced on Sep 28, 2023. It will be paid Dec 31, 2023 with an ex-dividend date of Dec 14, 2023. | Neutral | |
| 2023-11-14 05:14 EST | Dividend | A dividend of $0.2 has been announced on Sep 28, 2023. It will be paid Nov 30, 2023 with an ex-dividend date of Nov 14, 2023. | Neutral | |
| 2023-10-12 06:13 EST | Dividend | A dividend of $0.2 has been announced on Sep 28, 2023. It will be paid Oct 31, 2023 with an ex-dividend date of Oct 12, 2023. | Neutral | |
| 2023-09-14 06:16 EST | Dividend | A dividend of $0.2 has been announced on Jul 3, 2023. It will be paid Sep 30, 2023 with an ex-dividend date of Sep 14, 2023. | Neutral | |
| 2023-08-14 06:14 EST | Dividend | A dividend of $0.2 has been announced on Jul 3, 2023. It will be paid Aug 31, 2023 with an ex-dividend date of Aug 14, 2023. | Neutral | |
| 2023-07-13 06:13 EST | Dividend | A dividend of $0.2 has been announced on Jun 29, 2023. It will be paid Jul 31, 2023 with an ex-dividend date of Jul 13, 2023. | Neutral | |
| 2023-06-14 06:16 EST | Dividend | A dividend of $0.2 has been announced on May 25, 2023. It will be paid Jun 30, 2023 with an ex-dividend date of Jun 14, 2023. | Neutral | |
| 2023-05-12 06:14 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid May 31, 2023 with an ex-dividend date of May 12, 2023. | Neutral | |
| 2023-04-13 06:16 EST | Dividend | A dividend of $0.2 has been announced on Mar 28, 2023. It will be paid Apr 30, 2023 with an ex-dividend date of Apr 13, 2023. | Neutral | |
| 2023-03-31 16:15 EST | News | Fortress Biotech Non-GAAP EPS of -$0.33 misses by $0.18, revenue of $75.7M misses by $23.67M | N/A | |
| 2023-03-14 06:15 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Mar 31, 2023 with an ex-dividend date of Mar 14, 2023. | Neutral | |
| 2023-02-14 05:16 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Feb 28, 2023 with an ex-dividend date of Feb 14, 2023. | Neutral | |
| 2023-01-12 05:13 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Jan 31, 2023 with an ex-dividend date of Jan 12, 2023. | Neutral | |
| 2022-12-14 05:15 EST | Dividend | A dividend of $0.2 has been announced on Oct 5, 2022. It will be paid Dec 31, 2022 with an ex-dividend date of Dec 14, 2022. | Neutral | |
| 2022-11-15 14:13 EST | News | Fortress Biotech Non-GAAP EPS of -$0.08 misses by $0.01, revenue of $16.5M misses by $5.13M | N/A | |
| 2022-11-14 05:14 EST | Dividend | A dividend of $0.2 has been announced on Oct 5, 2022. It will be paid Nov 30, 2022 with an ex-dividend date of Nov 14, 2022. | Neutral | |
| 2022-11-11 05:15 EST | News | Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-10-13 06:20 EST | Dividend | A dividend of $0.2 has been announced on Oct 5, 2022. It will be paid Oct 31, 2022 with an ex-dividend date of Oct 13, 2022. | Neutral | |
| 2022-10-05 17:25 EST | News | Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 declares $0.1953 dividend | N/A | |
| 2022-09-14 06:15 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Sep 30, 2022 with an ex-dividend date of Sep 14, 2022. | Neutral | |
| 2022-08-12 06:13 EST | Dividend | A dividend of $0.2 has been announced on Jul 26, 2022. It will be paid Aug 31, 2022 with an ex-dividend date of Aug 12, 2022. | Neutral | |
| 2022-07-14 06:16 EST | Dividend | A dividend of $0.2 has been announced on May 25, 2022. It will be paid Jul 31, 2022 with an ex-dividend date of Jul 14, 2022. | Neutral | |
| 2022-06-14 06:13 EST | Dividend | A dividend of $0.2 has been announced on May 20, 2022. It will be paid Jun 30, 2022 with an ex-dividend date of Jun 14, 2022. | Neutral | |
| 2022-05-12 06:13 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid May 31, 2022 with an ex-dividend date of May 12, 2022. | Neutral | |
| 2022-04-13 06:12 EST | Dividend | A dividend of $0.2 has been announced on Apr 4, 2022. It will be paid Apr 30, 2022 with an ex-dividend date of Apr 13, 2022. | Neutral | |
| 2022-03-14 06:16 EST | Dividend | A dividend of $0.2 has been announced on Mar 1, 2022. It will be paid Mar 31, 2022 with an ex-dividend date of Mar 14, 2022. | Neutral | |
| 2022-02-14 05:14 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Feb 28, 2022 with an ex-dividend date of Feb 14, 2022. | Neutral | |
| 2022-02-12 10:41 EST | News | Fortress Biotech (FBIO) Investor Presentation - Slideshow | N/A | |
| 2022-01-13 05:14 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Jan 31, 2022 with an ex-dividend date of Jan 13, 2022. | Neutral | |
| 2021-12-14 05:19 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Dec 31, 2021 with an ex-dividend date of Dec 14, 2021. | Neutral | |
| 2021-11-12 05:16 EST | Dividend | A dividend of $0.2 has been announced on Nov 3, 2021. It will be paid Nov 30, 2021 with an ex-dividend date of Nov 12, 2021. | Neutral | |
| 2021-10-14 06:20 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Oct 30, 2021 with an ex-dividend date of Oct 14, 2021. | Neutral | |
| 2021-08-12 06:20 EST | Dividend | A dividend of $0.2 has been announced on Aug 3, 2021. It will be paid Aug 30, 2021 with an ex-dividend date of Aug 12, 2021. | Neutral | |
| 2021-07-14 06:19 EST | Dividend | A dividend of $0.2 has been announced on Jul 1, 2021. It will be paid Jul 30, 2021 with an ex-dividend date of Jul 14, 2021. | Neutral | |
| 2021-06-14 06:28 EST | Dividend | A dividend of $0.2 has been announced on Jun 8, 2021. It will be paid Jun 30, 2021 with an ex-dividend date of Jun 14, 2021. | Neutral | |
| 2021-05-13 06:22 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid May 30, 2021 with an ex-dividend date of May 13, 2021. | Neutral | |
| 2021-04-14 06:17 EST | Dividend | A dividend of $0.2 has been announced on Apr 5, 2021. It will be paid Apr 30, 2021 with an ex-dividend date of Apr 14, 2021. | Neutral | |
| 2021-03-12 05:20 EST | Dividend | A dividend of $0.2 has been announced on Mar 8, 2021. It will be paid Mar 31, 2021 with an ex-dividend date of Mar 12, 2021. | Neutral | |
| 2021-02-11 05:21 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Feb 28, 2021 with an ex-dividend date of Feb 11, 2021. | Neutral | |
| 2020-12-14 05:20 EST | Dividend | A dividend of $0.2 has been announced on Nov 30, -0001. It will be paid Dec 31, 2020 with an ex-dividend date of Dec 14, 2020. | Neutral | |
| 2020-12-04 06:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 08:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 05:17 EST | Dividend | A dividend of $0.2 has been announced on N/A. It will be paid Nov 30, 2020 with an ex-dividend date of Nov 12, 2020. | Neutral | |
| 2020-11-11 07:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-14 06:14 EST | Dividend | A dividend of $0.2 has been announced on Oct 1, 2020. It will be paid Oct 31, 2020 with an ex-dividend date of Oct 14, 2020. | Neutral | |
About Fortress Biotech, Inc (FBIOP):
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
General
- Name Fortress Biotech, Inc
- Symbol FBIOP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 93
- Fiscal Year EndDecember
- IPO Date2017-11-14
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.fortressbiotech.com
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -132%
- Operating Margin -233%
- Return on Assets -24%
- Return on Equity -92%
- Revenue 42.98 million
- Earnings Per Share -$1.12
- Revenue Per Share $0.64
- Gross Profit 26.1 million
- Quarterly Earnings Growth -3%
View More
Highlights
- Market Capitalization 125.34 million
- EBITDA -115651000
- Book Value Per Share $1.04
View More
Share Statistics
- Shares Outstanding 56.68 million
- Shares Float 57.26 million
- % Held by Insiders <1%
- % Held by Institutions 9.03%
- Shares Short 541
- Shares Short Prior Month 1406
- Short Ratio 0.03
View More
Technicals
- Beta 2.45
- 52 Week High $23.54
- 52 Week Low $11.64
- 50 Day Moving Average 22.26
- 200 Day Moving Average 19.82
View More
Dividends
- Forward Annual Dividend Rate $2.34
- Forward Annual Dividend Yield 10.33%
- Dividend Date 2021-02-28
- ExDividend Date 2021-03-12
- Dividend Per Share $2.34
- Dividend Yield 13.61%
View More
Fortress Biotech, Inc (FBIOP) Dividend Calendar:
Fortress Biotech, Inc pays an annual dividend of $2.34 per share, with a dividend yield of 13.61%.
FBIOP's last dividend payment was made to shareholders on February 28, 2021.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Fortress Biotech, Inc (FBIOP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-06-30 | 2020-09-30 | $N/A | -$0.20 | -$0.27 | 24.33% |
| 2020-03-31 | 2020-06-30 | $12.92 million | -$0.19 | -$0.23 | 15.57% |
| 2019-12-31 | 2020-03-31 | $11.13 million | -$0.19 | -$0.31 | 37.16% |
| 2019-09-30 | 2019-12-31 | $9.77 million | -$0.26 | -$0.30 | 13.47% |
| 2019-06-30 | 2019-09-30 | $9.25 million | -$0.22 | -$0.46 | 51.2% |
| 2019-03-31 | 2019-06-30 | $6.48 million | -$0.24 | -$0.58 | 57.97% |
| 2018-12-31 | 2019-03-31 | $26.88 million | $0.02 | -$0.58 | 103.45% |
| 2018-09-30 | 2018-12-31 | $63.69 million | -$0.47 | -$0.55 | 15.24% |
| 2018-06-30 | 2018-09-30 | $63.83 million | -$0.43 | -$0.59 | 27.08% |
| 2018-03-31 | 2018-06-30 | $55.43 million | -$0.34 | -$0.43 | 21.23% |
| 2017-12-31 | 2018-03-31 | $197.41 million | -$0.45 | -$0.63 | 29.29% |
| 2017-09-30 | 2017-11-09 | $46.89 million | -$0.67 | -$0.42 | -59.52% |
| 2017-06-30 | 2017-09-30 | $83.35 million | -$0.67 | -$0.29 | -129.59% |
| 2017-03-31 | 2017-06-30 | $44.68 million | -$0.43 | -$0.36 | -18.94% |
| 2016-12-31 | 2017-03-31 | -$0.30 | -$0.31 | 4.23% | |
| 2016-09-30 | 2016-12-31 | -$0.43 | -$0.20 | -116.85% | |
| 2016-06-30 | 2016-09-30 | -$0.32 | -$0.29 | -11.55% | |
| 2016-03-31 | 2016-06-30 | -$0.31 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.31 | -$0.09 | -242% | |
| 2015-09-30 | 2015-12-31 | $25000 | -$0.30 | -$0.13 | -134.54% |
| 2015-06-30 | 2015-09-30 | $N/A | -$0.46 | -$0.14 | -229.14% |
| 2015-03-31 | 2015-06-30 | -$0.16 | -$0.11 | -43.45% | |
| 2014-12-31 | 2015-03-31 | -$0.31 | |||
| 2014-09-30 | 2014-12-31 | -$0.10 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.13 | -$0.18 | 29.17% | |
| 2014-03-31 | 2014-06-30 | -$0.13 | -$0.20 | 34.6% | |
| 2013-12-31 | 2014-03-31 | -$0.21 | -$0.22 | 6.68% | |
| 2013-09-30 | 2013-12-31 | $N/A | -$0.27 | -$0.31 | 11.39% |
| 2013-06-30 | 2013-09-30 | $N/A | -$0.24 | -$0.34 | 29.41% |
| 2013-03-31 | 2013-06-30 | $N/A | -$0.38 | -$0.30 | -26.6% |
| 2012-12-31 | 2013-03-31 | -$0.35 | -$0.28 | -25.64% | |
| 2012-09-30 | 2012-12-31 | -$0.36 | -$0.28 | -26.89% | |
| 2012-06-30 | 2012-09-30 | -$0.24 | -$0.40 | 39.13% | |
| 2012-03-31 | 2012-06-30 | -$0.34 | -$0.31 | -8.48% | |
| 2011-12-31 | 2012-03-31 | -$0.35 | -$0.32 | -10.13% | |
| 2011-09-30 | 2011-12-31 | -$0.52 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.48 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$1.64 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$4.71 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.34 | $0.00 |
Fortress Biotech, Inc (FBIOP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 15.12 million | 23.62 million | 15.27 million |
| Income Before Tax | N/A | N/A | -24.07 million | -32.96 million | -24.97 million |
| Selling General Administrative | N/A | N/A | 15.52 million | 14.33 million | 14.34 million |
| Gross Profit | N/A | N/A | 9.11 million | 7.57 million | 7.07 million |
| Ebit | N/A | N/A | -19.66 million | -28.58 million | -20.57 million |
| Operating Income | N/A | N/A | -21.53 million | -30.38 million | -22.54 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | 12.92 million | 11.13 million | 9.77 million |
| Cost of Revenue | N/A | N/A | 3.81 million | 3.56 million | 2.7 million |
| Total Other Income Expense Net | N/A | N/A | -42000 | -72000 | -2.43 million |
| Net Income From Continuing Operations | N/A | N/A | -24.07 million | -32.96 million | -24.97 million |
| Net Income Applicable to Common Shares | -15.55 million | -13.31 million | -12.37 million | -15.49 million | -12.76 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -2.76 million | N/A | -1.78 million | 310000 | -3.75 million |
| Change to Liabilities | 1.22 million | -3.28 million | -599000 | 5.94 million | 4.81 million |
| Total Cash Flow from Investing Activities | -2.76 million | -1.06 million | -1.78 million | 310000 | -3.75 million |
| Net Borrowings | -29.67 million | N/A | -33000 | N/A | -67000 |
| Total Cash Flow from Financial Activities | 46.83 million | N/A | 22.75 million | 27.16 million | 5.55 million |
| Change to Operating Activities | -130000 | 1.67 million | -1.58 million | -80000 | -1.13 million |
| Change in Cash | 20.18 million | N/A | -915000 | 2.41 million | -14.46 million |
| Total Cash from Operating Activities | -23.89 million | -17.41 million | -21.89 million | -25.05 million | -16.26 million |
| Depreciation | 1.34 million | N/A | 1.29 million | 1.27 million | 1.23 million |
| Other Cash Flow from Investing Activities | N/A | N/A | -1.25 million | 24.84 million | -3.25 million |
| Change to Inventory | 157000 | N/A | 88000 | 84000 | -209000 |
| Change to Account Receivables | -4.45 million | N/A | -2.27 million | -8.25 million | -2.03 million |
| Other Cash Flow from Financing Activities | 43.07 million | 38.67 million | 3.59 million | 16.99 million | 3.64 million |
| Change to Net Income | -10.39 million | -8.6 million | -7.2 million | -9.38 million | -7.1 million |
| Capital Expenditures | 2.76 million | N/A | 1.78 million | 4.69 million | 3.75 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 153.47 million | 153.89 million | 146.59 million |
| Total Stockholder Equity | N/A | N/A | 37.23 million | 26.22 million | 25.8 million |
| Other Current Liabilities | 3 million | N/A | 69000 | 27000 | 26 million |
| Total Assets | N/A | N/A | 228.76 million | 226.42 million | 221.59 million |
| Common Stock | 94000 | 86000 | 79000 | 74000 | 70000 |
| Other Current Assets | N/A | N/A | 43.77 million | 44.14 million | 59.85 million |
| Retained Earnings | -477.47 million | -461.92 million | -448.6 million | -436.23 million | -420.74 million |
| Other Liabilities | 8.21 million | 7.34 million | 2.09 million | 2.14 million | 2.18 million |
| Other Assets | 3 million | 17.92 million | 17.93 million | 17.73 million | 2.32 million |
| Cash | N/A | N/A | 135.94 million | 136.86 million | 134.95 million |
| Total Current Liabilities | 37.28 million | N/A | 51.73 million | 45.62 million | 46.85 million |
| Other Stockholder Equity | 18000 | 813000 | 661000 | 500000 | 500000 |
| Property, Plant & Equipment | 32.38 million | 33.04 million | 33.86 million | 33.91 million | 34.03 million |
| Total Current Assets | 237.74 million | N/A | 158.8 million | 156.25 million | 166.31 million |
| Long Term Investments | N/A | N/A | 11.15 million | 11.15 million | 11.19 million |
| Net Tangible Assets | 86.07 million | 53.81 million | 30.2 million | 18.84 million | 18.06 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 5 million |
| Long Term Debt | N/A | N/A | 76.01 million | 82.43 million | 73.38 million |
| Inventory | 1.05 million | N/A | 769000 | 857000 | 941000 |
| Accounts Payable | 32.56 million | N/A | 34.21 million | 35.45 million | 28.51 million |
Fortress Biotech, Inc (FBIOP) Chart:
Fortress Biotech, Inc (FBIOP) News:
Below you will find a list of latest news for Fortress Biotech, Inc (FBIOP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Fortress Biotech, Inc (FBIOP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest FBIOP Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:48 PM EST | 100 | $18.07 |
Fortress Biotech, Inc (FBIOP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920075304/0001104659-20-075304-index.htm |
| 2020-04-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1429260/000000000020003526/0000000000-20-003526-index.htm |
| 2020-05-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1429260/000000000020003776/0000000000-20-003776-index.htm |
| 2020-05-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1429260/000000000020004603/0000000000-20-004603-index.htm |
| 2019-12-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465919077300/0001104659-19-077300-index.htm |
| 2019-12-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465919077302/0001104659-19-077302-index.htm |
| 2020-01-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920006941/0001104659-20-006941-index.htm |
| 2020-01-27 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1429260/000110465920006943/0001104659-20-006943-index.htm |
| 2020-02-12 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1429260/000110465920017538/0001104659-20-017538-index.htm |
| 2020-02-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920019375/0001104659-20-019375-index.htm |
| 2020-02-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920019384/0001104659-20-019384-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033108/0001104659-20-033108-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033109/0001104659-20-033109-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033110/0001104659-20-033110-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033113/0001104659-20-033113-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033114/0001104659-20-033114-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033116/0001104659-20-033116-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033117/0001104659-20-033117-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033118/0001104659-20-033118-index.htm |
| 2020-03-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920034133/0001104659-20-034133-index.htm |
| 2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920034151/0001104659-20-034151-index.htm |
| 2020-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920037129/0001104659-20-037129-index.htm |
| 2020-04-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1429260/000110465920048248/0001104659-20-048248-index.htm |
| 2020-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1429260/000110465920051629/0001104659-20-051629-index.htm |
| 2020-04-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1429260/000110465920051639/0001104659-20-051639-index.htm |
| 2020-04-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1429260/000110465920052637/0001104659-20-052637-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920059592/0001104659-20-059592-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920059608/0001104659-20-059608-index.htm |
| 2020-05-18 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920062808/0001104659-20-062808-index.htm |
| 2020-05-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920063846/0001104659-20-063846-index.htm |
| 2020-05-19 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1429260/000110465920063851/0001104659-20-063851-index.htm |
| 2020-05-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1429260/000110465920065677/0001104659-20-065677-index.htm |
| 2020-05-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1429260/000110465920065844/0001104659-20-065844-index.htm |
| 2020-05-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920067124/0001104659-20-067124-index.htm |
| 2020-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920067133/0001104659-20-067133-index.htm |
| 2020-05-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920067828/0001104659-20-067828-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920067844/0001104659-20-067844-index.htm |
| 2020-06-02 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1429260/000110465920068690/0001104659-20-068690-index.htm |
| 2020-06-04 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1429260/000110465920069663/0001104659-20-069663-index.htm |
| 2020-06-12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1429260/000110465920072973/0001104659-20-072973-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920075304/0001104659-20-075304-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920092702/0001104659-20-092702-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920092784/0001104659-20-092784-index.htm |
| 2020-08-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920097782/0001104659-20-097782-index.htm |
| 2020-08-24 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1429260/000110465920097784/0001104659-20-097784-index.htm |
| 2020-08-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920099792/0001104659-20-099792-index.htm |
| 2020-08-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1429260/000110465920099794/0001104659-20-099794-index.htm |
| 2020-08-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1429260/000110465920099802/0001104659-20-099802-index.htm |
| 2020-09-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920101100/0001104659-20-101100-index.htm |
| 2020-09-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920101102/0001104659-20-101102-index.htm |
| 2020-09-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1429260/000110465920109014/0001104659-20-109014-index.htm |
| 2020-06-03 | PX14A6G | Notice of exempt solicitation submitted by non-management | https://www.sec.gov/Archives/edgar/data/1429260/000114036120012974/0001140361-20-012974-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1429260/000149315220002531/0001493152-20-002531-index.htm |
| 2020-05-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1429260/999999999520001254/9999999995-20-001254-index.htm |
Fortress Biotech, Inc (FBIOP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fortress Biotech, Inc (FBIOP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: < 1%Institutional Ownership: 903%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-01-01 | MICHAEL S WEISS | EXECUTIVE VICE CHAIRMAN | Buy | 801,536.00 | 10,201,811.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033118/0001104659-20-033118-index.htm | ||
| 2020-01-01 | J JAY LOBELL | Director | Buy | 100,000.00 | 1,036,000.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033113/0001104659-20-033113-index.htm | ||
| 2020-01-01 | Kevin Lorenz | Director | Buy | 50,000.00 | 164,582.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033114/0001104659-20-033114-index.htm | ||
| 2020-08-26 | Malcolm Hoenlein | Director | Buy | 16,667.00 | 18.00 | 300,006.00 | 16,667.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920101102/0001104659-20-101102-index.htm |
| 2020-09-22 | Robyn Hunter | Chief Financial Officer | Sell | 28,450.00 | 4.38 | 124,611.00 | 192,169.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920109014/0001104659-20-109014-index.htm |
| 2019-06-03 | Robyn Hunter | Chief Financial Officer | Buy | 2,297.00 | 1.10 | 2,526.70 | 220,619.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465919077302/0001104659-19-077302-index.htm |
| 2020-01-01 | Malcolm Hoenlein | Director | Buy | 50,000.00 | 385,000.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033109/0001104659-20-033109-index.htm | ||
| 2020-01-01 | Dov Klein | Director | Buy | 100,000.00 | 555,000.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033110/0001104659-20-033110-index.htm | ||
| 2020-01-01 | Eric K Rowinsky | Director | Buy | 100,000.00 | 650,000.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033117/0001104659-20-033117-index.htm | ||
| 2020-01-01 | Jimmie Harvey | Director | Buy | 100,000.00 | 650,000.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033108/0001104659-20-033108-index.htm | ||
| 2019-06-03 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | Buy | 1,467.00 | 1.10 | 1,613.70 | 8,571,189.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033116/0001104659-20-033116-index.htm |
| 2019-12-01 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | Buy | 1,123.00 | 2.06 | 2,313.38 | 8,572,312.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033116/0001104659-20-033116-index.htm |
| 2020-08-26 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | Buy | 52,500.00 | 18.00 | 945,000.00 | 92,500.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920101100/0001104659-20-101100-index.htm |
| 2020-01-01 | LINDSAY A MD ROSENWALD | PRESIDENT, CEO & CHAIRMAN | Buy | 801,536.00 | 9,373,848.00 | https://www.sec.gov/Archives/edgar/data/1429260/000110465920033116/0001104659-20-033116-index.htm |